UCB aspires to be the patient-centric global biopharmaceutical leader, transforming the lives of people living with serious diseases. The company employs more than 8 000 people dedicated to the research, development and commercialisation of innovative medicines and patient solutions. Operating in more than 40 countries, UCB generated revenues of € 3.2 billion in 2011.